Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Lasa Supergenerics Ltd - 540702 - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. August 26, 2022

 Pursuant to Regulation 30 of SEBI (Listing Obligation and Discourse Requirement) Regulation 2015 we would like to inform you that the Board of Directors at their meeting held today which commenced at 01:00 p.m. and concluded at 03:30 p.m. have considered and approved the following: 1) The Notice of the Seventh (7th) Annual general Meeting (AGM) of the Company. 2) The 7th AGM is scheduled to be held on Monday, September 26, 2022 at 9.30 a.m. through Video conferencing (VC) / Other Audio-Visual means (OAVM).
26-08-2022
Bigul

Lasa Supergenerics Ltd - 540702 - Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. August 08, 2022

 considered and approved the following: 1. The statement of unaudited Financial Results of the Company for the Quarter Ended on June 30, 2022. 2. Limited Review Report from Statutory Auditor for the quarter ended on June 30, 2022. 3. Re appointment of Ms. Manali Bhagtani (DIN: 08067867) as an Independent Director of the Company for the second term of 5 years. The brief profile of the Independent Director is enclosed as Annexure-I.
08-08-2022
Bigul

Lasa Supergenerics Ltd - 540702 - Board Meeting Intimation for Consider, Approve And Take On Record Of Un-Audited Financial Results Along With Limited Review Report For The Quarter Ended June 30, 2022 And / Or To Discuss And Any Other Business / Matter With The Permission Of Chair.

 Lasa Supergenerics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2022 ,inter alia, to consider and approve and take on record of Un-audited financial results along with limited review report for the quarter ended June 30, 2022 and / or to discuss and any other business / matter with the permission of chair.
02-08-2022
Bigul

Lasa Supergenerics Ltd - 540702 - Announcement under Regulation 30 (LODR)-Change in Corporate Office Address

 In Compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that Corporate office of the company is shifted to Office No. 506 & 507, 5th Floor, Midas Sahar Plaza, Andheri Kurla Road, Andheri East - 400059.
20-07-2022
Bigul

Lasa Supergenerics Ltd - 540702 - Statement Of Investor Complaints For The Quarter Ended June 2022

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Ankita ShettyDesignation :- Company Secretary and Compliance Officer
13-07-2022
Bigul

Lasa Supergenerics Ltd - 540702 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Please find enclosed herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2022 received from Bigshare Services Private Limited, Registrar and Share Transfer Agent of the Company.
13-07-2022
Bigul

Lasa Supergenerics Ltd - 540702 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.

 The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 01, 2022 for Omkar Pravin Herlekar
01-07-2022
Bigul

Lasa Supergenerics Ltd - 540702 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Omkar Pravin Herlekar
01-07-2022
Bigul

Lasa Supergenerics Ltd - 540702 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for BNP Enterprises
01-07-2022
Bigul

Lasa Supergenerics Ltd - 540702 - Closure of Trading Window

 This is to inform you that as per the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders in terms of (Prohibition of Insider Trading) Regulations, 2015, as amended, the trading window for dealing in the equity shares of the Company has been closed for designated employees and their immediate relatives w.e.f. July 01, 2022 till 48 hours after the declaration of unaudited financial results (both days inclusive) for the quarter ended June 30, 2022.
30-06-2022
Next Page
Close

Let's Open Free Demat Account